Intravitreal Bevasizumab Versus Intravitreal Triamcinolone in Branch Retinal Vein Occlusion (BRVO)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01044329|
Recruitment Status : Unknown
Verified January 2010 by Shahid Beheshti University of Medical Sciences.
Recruitment status was: Recruiting
First Posted : January 7, 2010
Last Update Posted : January 7, 2010
|Condition or disease||Intervention/treatment||Phase|
|Branch Retinal Vein Occlusion||Drug: Bevacizumab Drug: Triamcinolone Acetonide||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||90 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Three Injections of Intravitreal Bevasizumab Versus Two Injections of Intravitreal Triamcinolone in the Management of Branch Retinal Vein Occlusion|
|Study Start Date :||January 2010|
|Estimated Primary Completion Date :||August 2010|
|Estimated Study Completion Date :||December 2010|
|Active Comparator: Intravitreal bevacizumab||
Intravitreal, 1.25 mg, 3 times, one month apart.
|Active Comparator: Intravitreal triamcinolone||
Drug: Triamcinolone Acetonide
Intravitreal, 2 mg, 2 times, two months apart.
- Visual acuity [ Time Frame: 6 months ]
- central macular thickness [ Time Frame: 6 months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01044329
|Iran, Islamic Republic of|
|Imam Hossein medical center||Recruiting|
|Tehran, Iran, Islamic Republic of|
|Contact: Alireza Ramezani, Assistant professor firstname.lastname@example.org|
|Principal Investigator: Alireza Ramezani, Assistant professor|